Pre-treatment of deceased organ donors with methylprednisolone versus placebo for the prevention of post-ischemic acute renal transplant failure

ISRCTN ISRCTN78828338
DOI https://doi.org/10.1186/ISRCTN78828338
Secondary identifying numbers P-18325
Submission date
14/03/2006
Registration date
12/04/2006
Last edited
04/11/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof Rainer Oberbauer
Scientific

Vienna Medical University
Waehringer Gürtel 18-20
Vienna
1090
Austria

Phone +43 (0)140 400 4358
Email rainer.oberbauer@meduniwien.ac.at

Study information

Study designRandomised placebo-controlled study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typePrevention
Scientific title
Study objectivesDeceased organ donors exhibit a severe systemic inflammatory response caused by the brain death syndrome. This leads to an activation of inflammatory regulators in the donor kidney, associated with increased risk for subsequent development of post-ischemic acute renal transplant failure (ARTF) in the recipient. ARTF is the main risk factor for shortened allograft survival. Pre-treatment of deceased organ donors with corticosteroids before organ retrieval may modify the genome-wide gene expression in the donor kidney and thus reduce the incidence and duration of post-ischemic ARTF after engraftment.
Ethics approval(s)Approved by the Ethics Committee of the Medical University Vienna on 14/03/2005, reference number: 067/2005
Health condition(s) or problem(s) studiedPre-treatment of deceased organ donors
InterventionThe deceased organ donor will be randomized to receive 1000 mg of methylprednisolone or placebo three to six hours before organ retrieval. Donor kidney biopsies will be obtained before engraftment and genome-wide gene expression analysis will be performed using complementary deoxyribonucleic acid (cDNA) microarrays.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Methylprednisolone
Primary outcome measureIncidence and duration of post-ischemic acute renal transplant failure in the transplant recipient
Secondary outcome measuresGenome-wide gene expression analysis of transplant kidney wedge biopsies
Overall study start date20/03/2006
Completion date20/09/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants200 deceased organ donors
Key inclusion criteriaDeceased kidney donors
Key exclusion criteriaNon-heart beating organ donors
Date of first enrolment20/03/2006
Date of final enrolment20/09/2008

Locations

Countries of recruitment

  • Austria

Study participating centre

Vienna Medical University
Vienna
1090
Austria

Sponsor information

Austrian Science Fund
Government

Weyringergasse 35
Vienna
1040
Austria

Phone +43 (0)1 505 67 40
Email office@fwf.ac.at
Website http://www.fwf.ac.at
ROR logo "ROR" https://ror.org/013tf3c58

Funders

Funder type

Government

Austrian Science Funds (grant P-18325)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 17/08/2010 Yes No